Noninvasive Vagus Nerve Stimulation for Migraine Treatment: The PRESTO Study

News
Slideshow

Noninvasive vagus nerve stimulation may be a viable method for the treatment of acute episodic migraine, according to a new study.

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose

Sydney Jennings
February 12th 2025
Article

Your daily dose of the clinical news you may have missed.

Distress Signals: How to Help a Clinician Colleague in Need

Distress Signals: How to Help a Clinician Colleague in Need

Sydney Jennings
February 14th 2023
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Heart Disease Remains Leading Cause of Death in US: Daily Dose / image credit: ©New Africa/AdobeStock

Heart Disease Remains Leading Cause of Death in US: Daily Dose

Sydney Jennings
February 11th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain / image credit ©fotogurmespb/stock.adobe.com

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain

Grace Halsey
February 10th 2025
Article

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose

Sydney Jennings
February 10th 2025
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.